CL2021002373A1 - Fármaco y método para tratar o prevenir las complicaciones de la diabetes utilizando dicho fármaco - Google Patents
Fármaco y método para tratar o prevenir las complicaciones de la diabetes utilizando dicho fármacoInfo
- Publication number
- CL2021002373A1 CL2021002373A1 CL2021002373A CL2021002373A CL2021002373A1 CL 2021002373 A1 CL2021002373 A1 CL 2021002373A1 CL 2021002373 A CL2021002373 A CL 2021002373A CL 2021002373 A CL2021002373 A CL 2021002373A CL 2021002373 A1 CL2021002373 A1 CL 2021002373A1
- Authority
- CL
- Chile
- Prior art keywords
- drug
- diabetes
- treating
- preventing complications
- complications
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019044670 | 2019-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021002373A1 true CL2021002373A1 (es) | 2022-06-17 |
Family
ID=72426033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021002373A CL2021002373A1 (es) | 2019-03-12 | 2021-09-10 | Fármaco y método para tratar o prevenir las complicaciones de la diabetes utilizando dicho fármaco |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220218664A1 (en, 2012) |
| EP (1) | EP3939659A4 (en, 2012) |
| JP (1) | JPWO2020184691A1 (en, 2012) |
| KR (1) | KR20220009371A (en, 2012) |
| CN (1) | CN114126711A (en, 2012) |
| AU (1) | AU2020238177A1 (en, 2012) |
| BR (1) | BR112021018084A8 (en, 2012) |
| CA (1) | CA3133204A1 (en, 2012) |
| CL (1) | CL2021002373A1 (en, 2012) |
| EA (1) | EA202192483A1 (en, 2012) |
| IL (1) | IL286289A (en, 2012) |
| MX (1) | MX2021011007A (en, 2012) |
| PE (1) | PE20220333A1 (en, 2012) |
| SG (1) | SG11202109982YA (en, 2012) |
| WO (1) | WO2020184691A1 (en, 2012) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220040294A (ko) * | 2020-09-23 | 2022-03-30 | 씨엔지바이오 주식회사 | 6-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물 |
| EP4293028A4 (en) * | 2021-02-10 | 2024-10-30 | Shanghai Senhui Medicine Co., Ltd. | Smtp-7 derivative and use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05176782A (ja) * | 1992-01-08 | 1993-07-20 | Taisho Pharmaceut Co Ltd | Ｎｇｆ作用増強因子 |
| JP2004224737A (ja) | 2003-01-23 | 2004-08-12 | Ttc:Kk | 新規トリプレニルフェノール化合物 |
| JP4313049B2 (ja) | 2003-01-23 | 2009-08-12 | 株式会社ティーティーシー | 血管新生関連疾患の予防又は治療用医薬組成物 |
| EP1944027A4 (en) | 2005-10-06 | 2009-08-19 | Univ Tokyo Nat Univ Corp | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF NEPHRITIS AND METHOD OF MANUFACTURE THEREOF |
| JP4395540B2 (ja) | 2006-03-27 | 2010-01-13 | 農工大ティー・エル・オー株式会社 | トリプレニルフェノール化合物及びトリプレニルフェノール化合物の製造方法並びに、血栓溶解促進剤 |
| WO2010110026A1 (ja) * | 2009-03-25 | 2010-09-30 | 国立大学法人東京農工大学 | メタボリックシンドローム、肥満、高血糖症、高脂血症および／又は脂肪肝のための医薬組成物 |
| EP2452679B1 (en) * | 2009-07-06 | 2014-05-28 | National University Corporation Tokyo University Of Agriculture and Technology | Triprenylphenolic cytoprotective agent |
| WO2011125930A1 (ja) * | 2010-04-02 | 2011-10-13 | 日本製薬株式会社 | 炎症性腸疾患又は自己免疫性の末梢神経障害の予防又は治療剤 |
| WO2012115209A1 (ja) * | 2011-02-24 | 2012-08-30 | 国立大学法人東京農工大学 | 可溶性エポキシドハイドロラーゼ阻害剤 |
| JP2019044670A (ja) | 2017-08-31 | 2019-03-22 | スズキ株式会社 | 内燃機関の排出ガス浄化システム |
-
2020
- 2020-03-12 WO PCT/JP2020/010967 patent/WO2020184691A1/ja not_active Application Discontinuation
- 2020-03-12 JP JP2021505150A patent/JPWO2020184691A1/ja not_active Withdrawn
- 2020-03-12 SG SG11202109982Y patent/SG11202109982YA/en unknown
- 2020-03-12 CA CA3133204A patent/CA3133204A1/en active Pending
- 2020-03-12 EP EP20771088.0A patent/EP3939659A4/en not_active Withdrawn
- 2020-03-12 PE PE2021001508A patent/PE20220333A1/es unknown
- 2020-03-12 US US17/438,801 patent/US20220218664A1/en not_active Abandoned
- 2020-03-12 KR KR1020217032312A patent/KR20220009371A/ko not_active Withdrawn
- 2020-03-12 MX MX2021011007A patent/MX2021011007A/es unknown
- 2020-03-12 BR BR112021018084A patent/BR112021018084A8/pt not_active Application Discontinuation
- 2020-03-12 EA EA202192483A patent/EA202192483A1/ru unknown
- 2020-03-12 CN CN202080035808.7A patent/CN114126711A/zh active Pending
- 2020-03-12 AU AU2020238177A patent/AU2020238177A1/en not_active Abandoned
-
2021
- 2021-09-10 CL CL2021002373A patent/CL2021002373A1/es unknown
- 2021-09-12 IL IL286289A patent/IL286289A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2020184691A1 (en, 2012) | 2020-09-17 |
| EP3939659A4 (en) | 2022-12-21 |
| US20220218664A1 (en) | 2022-07-14 |
| WO2020184691A1 (ja) | 2020-09-17 |
| KR20220009371A (ko) | 2022-01-24 |
| AU2020238177A1 (en) | 2021-11-04 |
| EA202192483A1 (ru) | 2021-12-24 |
| IL286289A (en) | 2021-10-31 |
| EP3939659A1 (en) | 2022-01-19 |
| BR112021018084A8 (pt) | 2022-10-04 |
| CA3133204A1 (en) | 2020-09-17 |
| SG11202109982YA (en) | 2021-10-28 |
| PE20220333A1 (es) | 2022-03-14 |
| BR112021018084A2 (en, 2012) | 2021-12-21 |
| MX2021011007A (es) | 2022-03-11 |
| CN114126711A (zh) | 2022-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001565A1 (es) | Composición farmacéutica para prevenir o tratar el cáncer, comprendiendo el polímorfo cristalino del hexoxido tetraarsénico. | |
| CR20150454A (es) | Compuestos amida para el tratamiento de vih | |
| BR112017014067A2 (pt) | composição para tratar doenças relacionadas a il-6 | |
| MX2013009957A (es) | Agente de control de endoparasitos. | |
| CL2012003162A1 (es) | Formulacion farmaceutica de administracion oral que comprende un compuesto derivado de 1-(beta-d-glucopiranosil)-3-(2-tienilmetil)benceno sustituido, un diluyente , un desintegrante, un aglutinante y un lubricante; composición farmaceutica; y metodo para tratar un trastorno mediado por transportadores de glucosa dependientes de sodio. | |
| PH12021551317A1 (en) | Modulators of trex1 | |
| CO2019002246A2 (es) | Compuesto heterocíclico nitrogenado bicíclico | |
| CL2021002373A1 (es) | Fármaco y método para tratar o prevenir las complicaciones de la diabetes utilizando dicho fármaco | |
| UY38559A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| CO2019011547A2 (es) | Compuesto sólido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol | |
| MX2021015654A (es) | Antagonista del receptor 2 de prostaglandina e2 (ep2). | |
| CO2021014266A2 (es) | Composiciones farmacéuticas inyectables y usos de las mismas | |
| ECSP21071644A (es) | Compuestos macrocíclicos como agonistas de sting | |
| UY39150A (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
| MX2021009971A (es) | Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos. | |
| CL2022002770A1 (es) | Nueva combinación de compuestos con superior actividad herbicida | |
| MX2020006055A (es) | Composiciones farmaceuticas implantables de isoxazolina y usos de las mismas. | |
| MX2023002482A (es) | Composicion farmaceutica para prevencion y/o tratamiento de prurito por dialisis que comprende antagonista de interleucina 31 (il-31) como ingrediente activo. | |
| BR112018076734A2 (pt) | compostos heterocíclicos anti-infecciosos e usos dos mesmos | |
| UY38934A (es) | Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica | |
| BR112021002126A2 (pt) | Composição para dispensação de vírus, e, método para preparação de uma composição para dispensação de vírus. | |
| CR20220006A (es) | Compuestos para tratar enfermedad respiratoria | |
| CL2022002729A1 (es) | Nueva combinación de compuestos con superior actividad herbicida | |
| CL2021002950A1 (es) | Agente de control de nematodos parasitarios de plantas y método para controlar nematodos parasitarios de plantas | |
| CL2022001314A1 (es) | Fármaco para el tratamiento o la prevención de la hemorragia cerebral, y método para el tratamiento o la prevención de la hemorragia cerebral con dicho fármaco |